PMID: 8937842Aug 1, 1996Paper

A multicenter study of the antimicrobial susceptibility of community-acquired lower respiratory tract pathogens in the United States, 1992-1994. The Alexander Project

Diagnostic Microbiology and Infectious Disease
J A Washington

Abstract

A multicenter, collaborative study was performed over a three-year period (1992-1994) to determine the antimicrobial susceptibilities of isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae from community-acquired lower respiratory tract infections. Isolates were collected from five geographically separated medical centers in the United States and sent to a central laboratory for antimicrobial susceptibility testing. Of 350, 536, and 372 isolates of H. influenzae collected from the five centers in 1992, 1993, and 1994, 26.3%, 28.2%, and 30.1%, respectively, were beta-lactamase-positive. All isolates of H. influenzae remained susceptible to ceftriaxone, doxycycline, ciprofloxacin, and ofloxacin over the three-year period. Between 95 and 100% of isolates of H. influenzae remained susceptible to amoxicillin-clavulanic acid cefixime, clarithromycin, and chloramphenicol over this same period. The prevalence of beta-lactamase-positive isolates of M. catarrhalis increased from 92.1% in 1992 to 93.8% in 1993 and to 96.5% in 1994; however, isolates of this species were highly susceptible to amoxicillin-clavulanic acid, the cephalosporins, the macrolides, the fluoroquinolones, chloramphenicol, doxycycli...Continue Reading

References

Aug 24, 1995·The New England Journal of Medicine·J HofmannR F Breiman
Apr 1, 1995·Antimicrobial Agents and Chemotherapy·T G EvansK Sosnowski

❮ Previous
Next ❯

Citations

Jan 5, 2002·Diagnostic Microbiology and Infectious Disease·C MendesUNKNOWN MYSTIC Study Group (Europe)
Jun 23, 1998·Diagnostic Microbiology and Infectious Disease·R N Jones, W R Wilson
Sep 13, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·P C Appelbaum
Dec 23, 1999·The Pediatric Infectious Disease Journal·J L Blumer
Jun 23, 1999·Mayo Clinic Proceedings·S Alvarez-Elcoro, M J Enzler
Feb 24, 2015·Journal of Veterinary Diagnostic Investigation : Official Publication of the American Association of Veterinary Laboratory Diagnosticians, Inc·Josephine M McHugh, Siwo R de Kloet
Oct 12, 1999·Clinics in Chest Medicine·J T Cross, G D Campbell
Jan 11, 2013·Journal of Clinical Microbiology·Eric A F SimõesUNKNOWN ARIVAC Consortium
Dec 22, 2006·Expert Review of Anti-infective Therapy·Daryl J Hoban, George G Zhanel

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.